Would you continue Jak inhibitor therapy in a patient with long standing, previously refractory RA in their 60s who was found to have stenosis of the left common femoral artery and no other history of arteriosclerotic disease?  

The concern for the use of Jak kinase inhibitors in RA patients over the age of 65 with at least one risk factor for cardiovascular disease comes from the Oral Surveillance Trial published in the NEJM in 2022. It is randomized, open-label non-inferiority study comparing cardiovascular safety (and ma...